戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  clarify the principles and underpinnings of metronomics.
2 performed to compare a low-dose, continuous, metronomic administration scheme with a more classical m
3              The METEORA-II trial compared a metronomic all-oral treatment with intravenous (IV) chem
4                 Growth-modulating effects of metronomic and maximum tolerated dose (MTD) regimens on
5                                 Whereas both metronomic and maximum tolerated dose delivery of CTX di
6  in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relaps
7  Using single-dose scenarios to match ADs in metronomic approach, led to significant increase in inje
8  in the dose-dense arm and 5.0 months in the metronomic arm).
9 s 80% for the dose-dense arm and 69% for the metronomic arm; median OS was 17.1 months (95% CI, 14.0
10                                              Metronomic AT101 therapy increased mouse survival, decre
11 ation at rest, during autonomic challenge by metronomic breathing, a Valsalva manoeuvre and active st
12 rajectory analyses that neoadjuvant low-dose metronomic chemotherapy (MCT) leads to a characteristic
13 the addition of low-dose nivolumab to triple metronomic chemotherapy (TMC) improved overall survival
14                                              Metronomic chemotherapy alone and combined with AEE788 r
15 concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
16  targeted to disrupt pericyte support, while metronomic chemotherapy and/or VEGFR inhibitors target c
17 ional form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which
18                                              Metronomic chemotherapy does not improve 6-month PFS, co
19 ge, 15 years; 40 male [76.9%]) and 56 to the metronomic chemotherapy group (median age, 13 years; 42
20  months in the placebo group vs 96.4% in the metronomic chemotherapy group (P = .24).
21             However, clinical development of metronomic chemotherapy has been hampered by a number of
22                                     Although metronomic chemotherapy has not been clinically approved
23 Although multiple mechanisms of benefit from metronomic chemotherapy have been proposed, how these me
24 e that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternativ
25                       In our previous study, metronomic chemotherapy improved survival in this settin
26                         Combination 3TSR and metronomic chemotherapy induced the greatest tumor regre
27                                We found that metronomic chemotherapy induces functional normalization
28  Although the antitumor activity produced by metronomic chemotherapy is attributed widely to antiangi
29                                Although oral metronomic chemotherapy is often used in progressive ped
30                                              Metronomic chemotherapy is the frequent administration o
31                                              Metronomic chemotherapy is usually associated with bette
32                     To compare the effect of metronomic chemotherapy on progression-free survival (PF
33 ly measured the response of tumors to either metronomic chemotherapy or radiation therapy, where the
34 ls and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition.
35 same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therap
36 rowth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against earl
37 s study was to evaluate intraperitoneal (IP) metronomic chemotherapy using sustained release paclitax
38                                  Triple oral metronomic chemotherapy with erlotinib, methotrexate, an
39 sed tumor growth with low side effects using metronomic chemotherapy with GA.
40                                              Metronomic chemotherapy, defined as frequent administrat
41                                           In metronomic chemotherapy, frequent drug administration at
42  protocol, involving sequential MTD and then metronomic chemotherapy, overlaid with multitargeted inh
43 ptions regarding the mechanisms of action of metronomic chemotherapy, resulting in a set of 6 minimal
44                                              Metronomic chemotherapy, the delivery of doses in a low,
45 0.18-0.81; P = .01) appeared to benefit from metronomic chemotherapy.
46 vessels is a key determinant of benefit from metronomic chemotherapy.
47  a deeper, systems-level appreciation of the metronomics concept.
48 r a maximum tolerated dose (MTD) regimen, a "metronomic" continuous low-dose regimen, or a "chemo-swi
49         The combination of immunotherapy and metronomic CTX therapy may be well suited to clinical ma
50                 Further analysis showed that metronomic CTX treatment did not delete cells with low e
51 with malignant pleural mesothelioma received metronomic cyclophosphamide and dendritic cell-based imm
52 nd that reduction of regulatory T cells with metronomic cyclophosphamide increased the efficacy of im
53           The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC.
54 ion, but then rapid regrowth, in contrast to metronomic cyclophosphamide plus imatinib, which produce
55         Mice receiving the immune modulatory metronomic cyclophosphamide schedule had a significant i
56 ation with other modalities such as low-dose metronomic cyclophosphamide.
57 gest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by e
58 efficacious benefits that can be achieved by metronomic delivery of BH3-mimetic drugs, in particular
59 Combining this immunotherapeutic regime with metronomic delivery of CTX resulted in antitumor activit
60  in the taxane-sensitive cell lines, whereas metronomic docetaxel plus AEE788 had an additive effect
61                                     In vivo, metronomic docetaxel resulted in significant reduction o
62 combination therapy may be most useful when "metronomic" doses of antineoplastic drugs are used, ther
63                                           As metronomic dosing has shown tumor control capability, ev
64  the endothelial compartment of a tumor when metronomic dosing is employed.
65 knowledge of the coupled dynamics underlying metronomic dosing is neither sufficiently well developed
66                                              Metronomic dosing of chemotherapy-defined as frequent ad
67            It was recently demonstrated that metronomic dosing of cyclophosphamide induces a strong a
68             The cytotoxic effects of MTD and metronomic dosing were tested with 3-(4,5-dimethylthiazo
69  antiangiogenic therapy can be engendered by metronomic dosing.
70 witch" regimen consisting of MTD followed by metronomic dosing.
71 l objective; and (2) that regularly spaced, "metronomic" dosing is the best way to achieve it.
72 ate cancer patients to analyze the impact of metronomic framework and various infusion durations (1-4
73                                Despite this, metronomic gemcitabine significantly inhibited tumor ang
74                                 Furthermore, metronomic gemcitabine yielded a 40%-50% decrease in tum
75 ure to gemcitabine was 14 times lower in the metronomic groups compared with the standard group.
76         Stable disease was maintained in the metronomic groups for up to 2 months after treatment com
77 reatments included maximum tolerated dose or metronomic (i.e., frequent low doses) scheduling of anti
78                                     Low-dose metronomic (LDM) chemotherapy, which utilizes lower, les
79 offered by combining clinically translatable metronomic low-dose chemotherapy and IP pharmacokinetics
80 ty in mCRC could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination o
81                                            A metronomic, low-dose schedule of decitabine and venetocl
82  adjuvant phase III trial to 1-year low-dose metronomic methotrexate-based chemotherapy or no mainten
83 rl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblas
84 xpression of Omomyc, we now demonstrate that metronomic Myc inhibition not only contains Ras-driven l
85  docetaxel in combination with either daily (metronomic) or weekly (bolus) doses of AT101.
86 ivity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent
87   In 4-week cycles, patients received either metronomic oral VEX or weekly IV paclitaxel.
88 , and alternating 21-day cycles of low-dose (metronomic) oral etoposide and cyclophosphamide, supplem
89   In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemina
90 of metastases but overall suggest use of the metronomic protocol.
91                                         Both metronomic protocols (0.5 and 1 mg/kg/day for 28 days) w
92 ly, our results confirmed the superiority of metronomic protocols in chemoresistant tumors in vivoCan
93               One arm received a 4-drug oral metronomic regimen of daily celecoxib and thalidomide wi
94                                              Metronomic regimens inhibited mobilization of CEPs (P <
95                                   Effects of metronomic regimens on circulating endothelial precursor
96         Based on the PBPK modeling approach, metronomic RPT appears to improve efficacy (RDP) in deli
97       We aimed to investigate a personalized metronomic RPT paradigm, employing multiple lower-dose a
98 n this study, we show that a 6-day repeating metronomic schedule of cyclophosphamide administration a
99 nal cytotoxic chemotherapy administered on a metronomic schedule.
100 etion occurred with slower kinetics with the metronomic schedule.
101 ugs delivered with maximum tolerated dose or metronomic scheduling.
102 ity to synchronize head movements with novel metronomic sounds presented at novel tempos.
103 gies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different gr
104                     Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR
105                  We examined the efficacy of metronomic taxanes alone and in combination with AEE788-
106                                    In vitro, metronomic taxanes caused endothelial cell toxicity at 1
107                          Both dose-dense and metronomic temozolomide regimens were well tolerated wit
108  that other therapies such as dose-dense and metronomic temozolomide regimens, targeted molecular age
109 re randomly assigned to dose-dense and 43 to metronomic temozolomide.
110 ly greater than that of high dose density or metronomic therapies.
111 template was applied to the development of a metronomic therapy backbone for neuroblastoma.
112                        The results show that metronomic therapy normalizes the tumor vasculature to i
113                             When beneficial, metronomic therapy seems to be associated with normaliza
114       We therefore investigated whether such metronomic therapy with the alkylating agent cyclophosph
115   Several novel treatment modalities such as metronomic therapy, angiogenesis inhibitors, vascular di
116                                              Metronomic therapy, defined as the frequent, low dose ad
117 as response after 6 months of antiangiogenic metronomic therapy.
118 d suggests guidelines for the optimal use of metronomic therapy.
119 ive approaches, to call a workshop on "Tumor Metronomics: Timing and Dose Level Dynamics" to explore
120 hronized or syncopated tapping relative to a metronomic tone.
121 st cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and p

 
Page Top